Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35139274

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Feb 10
First author
Schmid P

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Apr;19(4):220. doi: 10.1038/s41571-022-00614-4.
    note
    Source null
    related pmid
    35217781
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 May 5;386(18):1771. doi: 10.1056/NEJMc2203316.
    note
    Source null
    related pmid
    35507497
    relationship
    Comment in

Authors and identifiers

  1. name
    Schmid P
    type
    Author
  2. name
    Cortes J
    type
    Author
  3. name
    Dent R
    type
    Author
  4. name
    Pusztai L
    type
    Author
  5. name
    McArthur H
    type
    Author
  6. name
    Kümmel S
    type
    Author
  7. name
    Bergh J
    type
    Author
  8. name
    Denkert C
    type
    Author
  9. name
    Park YH
    type
    Author
  10. name
    Hui R
    type
    Author
  11. name
    Harbeck N
    type
    Author
  12. name
    Takahashi M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Schmid P
    type
    Author
  2. name
    Cortes J
    type
    Author
  3. name
    Dent R
    type
    Author
  4. name
    Pusztai L
    type
    Author
  5. name
    McArthur H
    type
    Author
  6. name
    Kümmel S
    type
    Author
  7. name
    Bergh J
    type
    Author
  8. name
    Denkert C
    type
    Author
  9. name
    Park YH
    type
    Author
  10. name
    Hui R
    type
    Author
  11. name
    Harbeck N
    type
    Author
  12. name
    Takahashi M
    type
    Author
bibliography ids
  1. nci-bib-1f70bb83149b76ae29945976
book metadata
content sha256
e6b13415517c2d48c8bd6cc173d91e78d6c15f58bda42df19f4e8c9295058017
document type
citation
dois
  1. 10.1056/NEJMoa2112651
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35139274
immutable id
pubmed:35139274@e6b13415517c2d48c8bd6cc173d91e78d6c15f58bda42df19f4e8c9295058017
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
6
name
The New England journal of medicine
nlm unique id
0255562
pages
556-567
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Apr;19(4):220. doi: 10.1038/s41571-022-00614-4.
    note
    Source null
    related pmid
    35217781
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 May 5;386(18):1771. doi: 10.1056/NEJMc2203316.
    note
    Source null
    related pmid
    35507497
    relationship
    Comment in
outcomes validated
false
pmid
35139274
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
16d26aea21d90c8a904de3f4e9e8232a010d96aab1c7fd129be4ba86369aa7d2
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb 10
precision
day
year
2022
publication types
  1. Journal Article
  2. Multicenter Study
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35139274/
title
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

Preserved source evidence · Not medical advice